Voyager Therapeutics Inc (VYGR) - Net Assets
Based on the latest financial reports, Voyager Therapeutics Inc (VYGR) has net assets worth $219.82 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($288.31 Million) and total liabilities ($68.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Voyager Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $219.82 Million |
| % of Total Assets | 76.25% |
| Annual Growth Rate | N/A |
| 5-Year Change | 94.25% |
| 10-Year Change | 77.3% |
| Growth Volatility | 4374.5 |
Voyager Therapeutics Inc - Net Assets Trend (2013–2024)
This chart illustrates how Voyager Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore VYGR total assets for the complete picture of this company's asset base.
Annual Net Assets for Voyager Therapeutics Inc (2013–2024)
The table below shows the annual net assets of Voyager Therapeutics Inc from 2013 to 2024. For live valuation and market cap data, see VYGR stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $299.76 Million | +26.84% |
| 2023-12-31 | $236.32 Million | +300.41% |
| 2022-12-31 | $59.02 Million | -37.91% |
| 2021-12-31 | $95.06 Million | -38.40% |
| 2020-12-31 | $154.32 Million | +55.08% |
| 2019-12-31 | $99.51 Million | +114.25% |
| 2018-12-31 | $46.45 Million | -65.35% |
| 2017-12-31 | $134.05 Million | -1.38% |
| 2016-12-31 | $135.92 Million | -19.61% |
| 2015-12-31 | $169.07 Million | +14614.88% |
| 2014-12-31 | $1.15 Million | +129.98% |
| 2013-12-31 | $-3.83 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Voyager Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 32235100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $55.00K | 0.02% |
| Other Comprehensive Income | $-407.00K | -0.14% |
| Other Components | $626.30 Million | 208.93% |
| Total Equity | $299.76 Million | 100.00% |
Voyager Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Voyager Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jacob Finance And Investments Ltd
TA:JCFN
|
$209.20 Million |
|
OP Bancorp
NASDAQ:OPBK
|
$209.20 Million |
|
KG Eco Technology Services Co. Ltd
KQ:151860
|
$209.27 Million |
|
ESSA Bancorp Inc
NASDAQ:ESSA
|
$209.29 Million |
|
Namyang Dairy
KO:003920
|
$209.00 Million |
|
Bank Amar Indonesia
JK:AMAR
|
$208.99 Million |
|
Smartbroker Holding AG
XETRA:SB1
|
$208.93 Million |
|
Vestel Elektronik Sanayi ve Ticaret AS
IS:VESTL
|
$208.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Voyager Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 236,320,000 to 299,760,000, a change of 63,440,000 (26.8%).
- Net loss of 65,002,000 reduced equity.
- Share repurchases of 19,305,000 reduced equity.
- New share issuances of 112,778,000 increased equity.
- Other comprehensive income decreased equity by 359,000.
- Other factors increased equity by 35,328,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-65.00 Million | -21.68% |
| Share Repurchases | $19.30 Million | -6.44% |
| Share Issuances | $112.78 Million | +37.62% |
| Other Comprehensive Income | $-359.00K | -0.12% |
| Other Changes | $35.33 Million | +11.79% |
| Total Change | $- | 26.84% |
Book Value vs Market Value Analysis
This analysis compares Voyager Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.72x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-8.28 | $3.76 | x |
| 2014-12-31 | $0.08 | $3.76 | x |
| 2015-12-31 | $40.34 | $3.76 | x |
| 2016-12-31 | $5.37 | $3.76 | x |
| 2017-12-31 | $5.00 | $3.76 | x |
| 2018-12-31 | $1.45 | $3.76 | x |
| 2019-12-31 | $2.77 | $3.76 | x |
| 2020-12-31 | $4.13 | $3.76 | x |
| 2021-12-31 | $2.52 | $3.76 | x |
| 2022-12-31 | $1.54 | $3.76 | x |
| 2023-12-31 | $5.30 | $3.76 | x |
| 2024-12-31 | $5.20 | $3.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Voyager Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -81.25%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.31x
- Recent ROE (-21.68%) is above the historical average (-153.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.28 Million |
| 2014 | -1420.10% | 0.00% | 0.00x | 10.01x | $-16.43 Million |
| 2015 | -17.55% | -171.18% | 0.08x | 1.36x | $-46.58 Million |
| 2016 | -29.57% | -282.65% | 0.08x | 1.39x | $-53.79 Million |
| 2017 | -52.74% | -697.56% | 0.05x | 1.38x | $-84.10 Million |
| 2018 | -190.09% | -1158.79% | 0.04x | 3.81x | $-92.93 Million |
| 2019 | -41.03% | -39.11% | 0.29x | 3.56x | $-50.78 Million |
| 2020 | 23.81% | 21.47% | 0.65x | 1.70x | $21.31 Million |
| 2021 | -69.47% | -176.49% | 0.19x | 2.04x | $-75.54 Million |
| 2022 | -78.63% | -113.45% | 0.26x | 2.70x | $-52.31 Million |
| 2023 | 56.00% | 52.93% | 0.71x | 1.49x | $108.70 Million |
| 2024 | -21.68% | -81.25% | 0.20x | 1.31x | $-94.98 Million |
Industry Comparison
This section compares Voyager Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Voyager Therapeutics Inc (VYGR) | $219.82 Million | 0.00% | 0.31x | $209.06 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene the… Read more